Literature DB >> 23493313

Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu.

J Domínguez-Herrera1, C Velasco, F Docobo-Pérez, J M Rodríguez-Martínez, R López-Rojas, A Briales, C Pichardo, P Díaz-de-Alba, J Rodríguez-Baño, A Pascual, J Pachón.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the impact of qnrA1, qnrB1 and qnrS1 on the in vivo efficacies of ciprofloxacin and levofloxacin in an experimental model of pneumonia caused by Escherichia coli.
METHODS: Two isogenic groups of E. coli transformants, based on two ATCC 25922 strains, with or without the GyrA mutation Ser83Leu, and carrying qnrA1, qnrB1 or qnrS1, were used in an experimental pneumonia model. The efficacies of ciprofloxacin (40 mg/kg/day) and levofloxacin (50 and 150 mg/kg/day) were evaluated.
RESULTS: For the pneumonia caused by the parental strains lacking qnr genes, both fluoroquinolones significantly (P<0.05) reduced the bacterial lung concentration by >7 log10 cfu/g against E. coli ATCC/pBK and between 5.09 and 6.34 log10 cfu/g against E. coli ATCC-S83L/pBK. The presence of any qnr genes in the strains of both isogenic groups diminished the reduction of bacterial lung concentration with any therapy (P<0.05). Furthermore, all therapeutic schemes reduced the percentage of positive blood cultures in both isogenic groups (P<0.05). Finally, the survival results suggest a higher mortality with the strains expressing qnr genes.
CONCLUSIONS: The presence of qnrA1, qnrB1 and qnrS1 in E. coli reduced the efficacy of ciprofloxacin and levofloxacin in a murine pneumonia model.

Entities:  

Keywords:  Enterobacteriaceae; mouse model; pharmacodynamics; pharmacokinetics

Mesh:

Substances:

Year:  2013        PMID: 23493313     DOI: 10.1093/jac/dkt063

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Plasmid-mediated quinolone resistance.

Authors:  George A Jacoby; Jacob Strahilevitz; David C Hooper
Journal:  Microbiol Spectr       Date:  2014-10

2.  Quantifying the impact of treatment history on plasmid-mediated resistance evolution in human gut microbiota.

Authors:  Burcu Tepekule; Pia Abel Zur Wiesch; Roger D Kouyos; Sebastian Bonhoeffer
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-30       Impact factor: 11.205

Review 3.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 4.  Transferable Mechanisms of Quinolone Resistance from 1998 Onward.

Authors:  Joaquim Ruiz
Journal:  Clin Microbiol Rev       Date:  2019-08-14       Impact factor: 26.132

5.  Plasmid-Mediated Quinolone Resistance (PMQR) Genes and Class 1 Integrons in Quinolone-Resistant Marine Bacteria and Clinical Isolates of Escherichia coli from an Aquacultural Area.

Authors:  Alexandra Tomova; Larisa Ivanova; Alejandro H Buschmann; Henry P Godfrey; Felipe C Cabello
Journal:  Microb Ecol       Date:  2017-06-23       Impact factor: 4.552

6.  SSTAR, a Stand-Alone Easy-To-Use Antimicrobial Resistance Gene Predictor.

Authors:  Tom J B de Man; Brandi M Limbago
Journal:  mSphere       Date:  2016-01-13       Impact factor: 4.389

7.  Fluoroquinolone Resistance Mechanisms and population structure of Enterobacter cloacae non-susceptible to Ertapenem in North-Eastern France.

Authors:  Thomas Guillard; Pascal Cholley; Anne Limelette; Didier Hocquet; Lucie Matton; Christophe Guyeux; Anne-Laure Lebreil; Odile Bajolet; Lucien Brasme; Janick Madoux; Véronique Vernet-Garnier; Coralie Barbe; Xavier Bertrand; Christophe de Champs On Behalf Of CarbaFrEst Group
Journal:  Front Microbiol       Date:  2015-10-23       Impact factor: 5.640

8.  Quinolone Resistance Reversion by Targeting the SOS Response.

Authors:  E Recacha; J Machuca; P Díaz de Alba; M Ramos-Güelfo; F Docobo-Pérez; J Rodriguez-Beltrán; J Blázquez; A Pascual; J M Rodríguez-Martínez
Journal:  mBio       Date:  2017-10-10       Impact factor: 7.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.